Testing an investigational drug for advanced lung or gut cancer
Part of Cancer clinical trials.
This Phase 1 trial tests BA3182, an investigational medicine, in people with advanced adenocarcinoma that cannot be removed by surgery. The goal is to see how the treatment works and whether it’s tolerated, and it may offer an option when standard options have been limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed adenocarcinoma that is advanced and cannot be removed by surgery or has spread to other places
- You are 18 years or older
- Your kidneys, liver, and blood counts meet the trial’s lab requirements
- You can do daily activities fairly well (ECOG performance status 0 or 1)
- Your heart health is not significantly affected by known heart disease
- You do not have uncontrolled brain metastases, uncontrolled autoimmune disease, or active virus infections like HIV or hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
This trial tests a new drug, BA1301, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if BA1301 can help shrink or control the cancer.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Hear when a new Advanced Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.